| 前收市價 | 1.8100 |
| 開市 | 0.5600 |
| 買盤 | 0.4000 |
| 賣出價 | 0.7000 |
| 拍板 | 40.00 |
| 到期日 | 2024-09-20 |
| 今日波幅 | 0.5600 - 0.5600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 542 |
BenzingaWhy Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
InvestorPlaceDouble-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 return is approximately 10%. At that rate the law of 72 states that an investor can expect their capital to double roughly every 7 years. Thus, those seeking 100% returns by 2025 will have to take some risks. There is effectively zero chance that an average strategy will double an investor’s returns within that time fra
Insider MonkeyArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript May 9, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and […]
